Table S1. Seroconversion rate of different antibodies in different patients

|  |  |  |  |
| --- | --- | --- | --- |
| 　 | Days after onset | Total seropositive conversion | Total seronegative conversion |
|  | 1-7 | 8-14 | 15-30 | 31-65 |
| Total Ab, p/n (%) | 　 | 　 | 　 | 　 |  |  |
| Asymptomatic | 8/17 (47.1) | 7/9 (77. 8) | 10/10 (100) | 17/17 (100) | 20/22 (90.9) | 0/18 (0) |
| Presymptomatic | 12/23 (52.2) | 13/17 (76.5) | 21/21 (100) | 27/28 (96.4) | 30/32 (93.8) | 2/29 (6.9) |
| Symptomatic | 5/8 (62.5) | 6/12 (50.0) | 17/17 (100) | 19/19 (100) | 19/19 (100) | 0/19 (0) |
| *p* (*p*1/*p*2/*p*3) | 0.86 | 0.29 | NA | 1.00 | 0.57 | 0.50 |
| IgG, p/n (%) |  |  |  |  |  |  |
| Asymptomatic | 8/17 (47.1) | 8/9 (88.9) | 10/10 (100) | 17/17 (100) | 21/22 (95.5) | 0/19 (0) |
| Presymptomatic | 13/23 (56.5) | 14/17 (82.4) | 21/21 (100) | 28/28 (100) | 30/32 (93.8) | 0/30 (0) |
| Symptomatic | 4/8 (50.0) | 8/12 (66.7) | 17/17 (100) | 19/19 (100) | 19/19 (100) | 0/19 (0) |
| *p* (*p*1/*p*2/*p*3) | 0.93 | 0.53 | NA | NA | 0.78 | NA |
| IgM, p/n (%) |  |  |  |  |  |  |
| Asymptomatic | 4/17 (23.5) | 2/9 (22.2) | 2/10 (20.0) | 5/17 (29.4) | 10/22 (45.5) | 4/8 (50.0) |
| Presymptomatic | 7/23 (30.4) | 8/17 (47.1) | 15/21 (71.4) | 10/28 (35.7) | 20/32 (62.5) | 11/20 (55.0) |
| Symptomatic | 1/8 (12.5) | 4/12 (33.3) | 11/17 (64.7) | 11/19 (57.9) | 12/19 (63.2) | 5/12 (41.7) |
| *p* (*p*1/*p*2/*p*3) | 0.75 | 0.48 | 0.02(0.02/0.04/0.66) | 0.17 | 0.39 | 0.91 |
| IgA, p/n (%) |  |  |  |  |  |  |
| Asymptomatic | 8/17 (47.06) | 7/9 (77.8) | 10/10 (100) | 17/17 (100) | 20/22 (90.9) | 0/18 (0) |
| Presymptomatic | 13/23 (56.52) | 13/17 (76.5) | 19/21 (90.5) | 22/28 (78.6) | 29/32 (90.6) | 6/28 (21.4) |
| Symptomatic | 5/8 (62.5) | 12/12 (100) | 17/17 (100) | 17/19 (89.5) | 19/19 (100) | 3/19 (15.8) |
| *p* (*p*1/*p*2/*p*3) | 0.79 | 0.20 | 0.68 | 0.10 | 0.51 | 0.11 |

p/n represents positive cases to total cases. NA (not available). *p*1, *p*2 and *p*3 were comparison between asymptomatic and presymptomatic, asymptomatic and symptomatic, presymptomatic and symptomatic, respectively. *p* value <0.05 indicates significant differences

Table S2. Peak concentration and time of different antibodies

|  |  |  |
| --- | --- | --- |
| 　 | Peak COI | Peak days after onset |
|  |
| Total Ab, mean ± SD (n) |  |  |
| Asymptomatic | 4.4±2.3 (n=18) | 36.56±15.49 (n=18) |
| Presymptomatic | 4.7±1.7 (n=29) | 36.7±14.1 (n=29) |
| Symptomatic | 5.7±0.9 (n=19) | 46.2±12.3 (n=19) |
| *p* (*p*1/*p*2/*p*3) | 0.06 | 0.51 |
| IgG, mean ± SD (n) |  |  |
| Asymptomatic | 3.5±1.3 (n=19) | 33.4±14.3 (n=19) |
| Presymptomatic | 3.9±1.0 (n=30) | 34.1±11.0 (n=30) |
| Symptomatic | 4.5±0.4 (n=19) | 38.7±11.5 (n=19) |
| *p* (*p*1/*p*2/*p*3) | 0.02 (0.47/0.01/0.12) | 0.35 |
| IgM, mean ± SD (n) |  |  |
| Asymptomatic | 0.8±0.6 (n=8) | 19.5±14.4 (n=8) |
| Presymptomatic | 1.8±1.3 (n=20) | 14.8±7.8 (n=20) |
| Symptomatic | 2.4±1.3 (n=12) | 24.2±7.7 (n=12) |
| *p* (*p*1/*p*2/*p*3) | 0.03 (0.19/0.02/0.33) | 0.04 (0.49/0.55/0.03) |
| IgA, mean ± SD (n) |  |  |
| Asymptomatic | 2.2±1.0 (n=18) | 21.8±14.8 (n=18) |
| Presymptomatic | 2.5±1.3 (n=27) | 16.7±10.1 (n=27) |
| Symptomatic | 2.7±1.0 (n=19) | 22.1±9.9 (n=19) |
| *p* (*p*1/*p*2/*p*3) | 0.50 | 0.22 |

*p*1, *p* 2 and *p* 3 were comparison between asymptomatic and presymptomatic, asymptomatic and symptomatic, presymptomatic and symptomatic, respectively. *p* value <0.05 indicates significant differences.